<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1303" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1303/" /><meta name="ncbi_pagename" content="Dysferlinopathy - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Dysferlinopathy - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Dysferlinopathy" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2015/03/05" /><meta name="citation_author" content="Masashi Aoki" /><meta name="citation_pmid" content="20301480" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1303/" /><meta name="citation_keywords" content="Miyoshi Distal Myopathy (Miyoshi Myopathy)" /><meta name="citation_keywords" content="Limb-Girdle Muscular Dystrophy Type 2B" /><meta name="citation_keywords" content="Dysferlin" /><meta name="citation_keywords" content="DYSF" /><meta name="citation_keywords" content="Dysferlinopathy" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Dysferlinopathy" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Masashi Aoki" /><meta name="DC.Date" content="2015/03/05" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1303/" /><meta name="description" content="Dysferlinopathy includes a spectrum of muscle disease characterized by two main phenotypes: Miyoshi myopathy with primarily distal weakness and limb-girdle muscular dystrophy type 2B (LGMD2B) with primarily proximal weakness. Miyoshi myopathy (median age of onset 19 years) is characterized by muscle weakness and atrophy, most marked in the distal parts of the legs, especially the gastrocnemius and soleus muscles. Over a period of years, the weakness and atrophy spread to the thighs and gluteal muscles. The forearms may become mildly atrophic with decrease in grip strength; the small muscles of the hands are spared. LGMD2B is characterized by early weakness and atrophy of the pelvic and shoulder girdle muscles in adolescence or young adulthood, with slow progression. Other phenotypes are scapuloperoneal syndrome, distal myopathy with anterior tibial onset, elevated serum CK concentration only, and congenital muscular dystrophy." /><meta name="og:title" content="Dysferlinopathy" /><meta name="og:type" content="book" /><meta name="og:description" content="Dysferlinopathy includes a spectrum of muscle disease characterized by two main phenotypes: Miyoshi myopathy with primarily distal weakness and limb-girdle muscular dystrophy type 2B (LGMD2B) with primarily proximal weakness. Miyoshi myopathy (median age of onset 19 years) is characterized by muscle weakness and atrophy, most marked in the distal parts of the legs, especially the gastrocnemius and soleus muscles. Over a period of years, the weakness and atrophy spread to the thighs and gluteal muscles. The forearms may become mildly atrophic with decrease in grip strength; the small muscles of the hands are spared. LGMD2B is characterized by early weakness and atrophy of the pelvic and shoulder girdle muscles in adolescence or young adulthood, with slow progression. Other phenotypes are scapuloperoneal syndrome, distal myopathy with anterior tibial onset, elevated serum CK concentration only, and congenital muscular dystrophy." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1303/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/miyoshi/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1303/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE88451CDFC83B210000000005AC028E.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1303_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1303_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/duarte-gal/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/dkc/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1303_"><span class="title" itemprop="name">Dysferlinopathy</span></h1><p class="contrib-group"><span itemprop="author">Masashi Aoki</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1303_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1303_ai__"><div class="contrib half_rhythm"><span itemprop="author">Masashi Aoki</span>, MD, PhD<div class="affiliation small">Department of Neurology<br />Tohoku University School of Medicine<br />Sendai, Japan<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="pj.ca.ukohot.dem@mikoa" class="oemail">pj.ca.ukohot.dem@mikoa</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">February 5, 2004</span>; Last Update: <span itemprop="dateModified">March 5, 2015</span>.</p><p><em>Estimated reading time: 16 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="miyoshi.Summary" itemprop="description"><h2 id="_miyoshi_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Dysferlinopathy includes a spectrum of muscle disease characterized by two main phenotypes: Miyoshi myopathy with primarily distal weakness and limb-girdle muscular dystrophy type 2B (LGMD2B) with primarily proximal weakness. Miyoshi myopathy (median age of onset 19 years) is characterized by muscle weakness and atrophy, most marked in the distal parts of the legs, especially the gastrocnemius and soleus muscles. Over a period of years, the weakness and atrophy spread to the thighs and gluteal muscles. The forearms may become mildly atrophic with decrease in grip strength; the small muscles of the hands are spared. LGMD2B is characterized by early weakness and atrophy of the pelvic and shoulder girdle muscles in adolescence or young adulthood, with slow progression. Other phenotypes are scapuloperoneal syndrome, distal myopathy with anterior tibial onset, elevated serum CK concentration only, and <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> muscular dystrophy.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>Diagnosis depends on a combination of muscle biopsy and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. Muscle biopsy western immunoblotting almost always indicates a primary dysferlinopathy. <i>DYSF</i>, which encodes the protein dysferlin, is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which pathogenic variants are known to cause dysferlinopathy.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Individualized management may include physical therapy, use of mechanical aids, surgical intervention for orthopedic complications, respiratory aids, and social and emotional support.</p><p><i>Prevention of secondary complications:</i> Stretching exercises to prevent contractures.</p><p><i>Surveillance:</i> Annual monitoring of muscle strength, joint range of motion, and respiratory function; and for evidence of cardiomyopathy for subtypes with cardiac involvement.</p><p><i>Agents/circumstances to avoid</i>: Weight control to avoid obesity; avoidance of steroid treatment.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Dysferlinopathy is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3. Carrier testing for at-risk relatives and <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for pregnancies at increased risk are possible if the pathogenic variants in the family are known.</p></div></div><div id="miyoshi.GeneReview_Scope"><h2 id="_miyoshi_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="miyoshi.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1303/table/miyoshi.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__miyoshi.Tc_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_miyoshi.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dysferlinopathy: Included Phenotypes&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_miyoshi.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Miyoshi distal myopathy (Miyoshi myopathy)</div></li><li class="half_rhythm"><div>Limb-girdle muscular dystrophy type 2B</div></li></ul></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#miyoshi.Nomenclature">Nomenclature</a>.</p></div></dd><dt>1. </dt><dd><div id="miyoshi.TF.c.1"><p class="no_margin">For other genetic causes of these phenotypes see <a href="#miyoshi.Differential_Diagnosis">Differential Diagnosis</a>.</p></div></dd></dl></div></div></div></div><div id="miyoshi.Diagnosis"><h2 id="_miyoshi_Diagnosis_">Diagnosis</h2><p>Dysferlinopathy caused by <i>DYSF</i> pathogenic variants includes a spectrum of muscle disease characterized mainly by two phenotypes: Miyoshi myopathy with primarily distal weakness and limb-girdle muscular dystrophy type 2B (LGMD2B) with primarily proximal weakness.</p><p><b>Miyoshi myopathy</b> is characterized by the following:</p><ul><li class="half_rhythm"><div>Mid- to late-childhood or early-adult onset; mean age at onset: 19.0 years [<a class="bk_pop" href="#miyoshi.REF.aoki.2001.271">Aoki et al 2001</a>]</div></li><li class="half_rhythm"><div>Early and predominant involvement of the calf muscles</div></li><li class="half_rhythm"><div>Slow progression</div></li><li class="half_rhythm"><div>Elevation of serum CK concentration, often 10-100 times normal; mean CK: 8,940 IU/L [<a class="bk_pop" href="#miyoshi.REF.aoki.2001.271">Aoki et al 2001</a>]</div></li><li class="half_rhythm"><div>Primarily myogenic pattern on EMG</div></li><li class="half_rhythm"><div>Biopsy evidence of a chronic, active myopathy without rimmed vacuoles</div></li></ul><p><b>LGMD2B</b> is characterized by the following:</p><ul><li class="half_rhythm"><div>Predominant weakness and atrophy of muscles of the pelvic and shoulder girdle</div></li><li class="half_rhythm"><div>Onset in the proximal lower-limb musculature in the late teens or later</div></li><li class="half_rhythm"><div>Massive elevation of serum CK concentration</div></li><li class="half_rhythm"><div>Slow progression</div></li><li class="half_rhythm"><div>Subclinical involvement of distal muscles, identified by careful examination or ancillary investigations such as muscle CT scan (in some individuals)</div></li></ul><div id="miyoshi.Testing"><h3>Testing</h3><p><b>Muscle biopsy</b></p><ul><li class="half_rhythm"><div><b>Histology.</b> Muscle biopsy shows evidence of a dystrophy with random variation in fiber size and evidence of degeneration and regeneration. Type one fibers may predominate. There is often evidence of inflammation, sometimes leading to a misdiagnosis of polymyositis [<a class="bk_pop" href="#miyoshi.REF.gallardo.2001.2136">Gallardo et al 2001</a>, <a class="bk_pop" href="#miyoshi.REF.fanin.2002.461">Fanin &#x00026; Angelini 2002</a>, <a class="bk_pop" href="#miyoshi.REF.serratrice.2002.1025">Serratrice et al 2002</a>, <a class="bk_pop" href="#miyoshi.REF.prelle.2003.537">Prelle et al 2003</a>].</div></li><li class="half_rhythm"><div><b>Immunostaining.</b> Antibodies to dysferlin identify a protein of approximately 230 kd and show that dysferlin is located in the muscle membrane [<a class="bk_pop" href="#miyoshi.REF.anderson.1999.855">Anderson et al 1999</a>, <a class="bk_pop" href="#miyoshi.REF.matsuda.1999.1119">Matsuda et al 1999</a>, <a class="bk_pop" href="#miyoshi.REF.eymard.2000.161">Eymard et al 2000</a>]. Most individuals with <i>DYSF</i> pathogenic variants show complete deficiency of the protein or sometimes patchy sarcolemmal and cytoplasmic staining on muscle biopsy. Many individuals with partial deficiency of dysferlin have been reported [<a class="bk_pop" href="#miyoshi.REF.piccolo.2000.902">Piccolo et al 2000</a>, <a class="bk_pop" href="#miyoshi.REF.matsuda.2001.1761">Matsuda et al 2001</a>, <a class="bk_pop" href="#miyoshi.REF.saito.2002.615">Saito et al 2002</a>].</div></li><li class="half_rhythm"><div><b>Immunoblot.</b> Because of variable and nonspecific patterns, immunoblot is generally considered the more reliable method for testing. If possible, both immunostaining and immunoblotting should be performed [<a class="bk_pop" href="#miyoshi.REF.tagawa.2003.23">Tagawa et al 2003</a>].</div></li></ul><p><b>Dysferlin expression.</b> In individuals with dysferlinopathy, dysferlin immunoreactivity in peripheral blood monocytes cannot be detected using a commercially available monoclonal antibody [<a class="bk_pop" href="#miyoshi.REF.ho.2002.129">Ho et al 2002</a>, <a class="bk_pop" href="#miyoshi.REF.ankala.2014.333">Ankala et al 2014</a>].</p><div id="miyoshi.Molecular_Genetic_Testing"><h4>Molecular Genetic Testing</h4><p><b>Gene.</b>
<i>DYSF</i>, which encodes the protein dysferlin, is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which pathogenic variants are known to cause dysferlinopathy.</p><div id="miyoshi.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Dysferlinopathy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1303/table/miyoshi.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__miyoshi.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_miyoshi.T.molecular_genetic_testing_used_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_miyoshi.T.molecular_genetic_testing_used_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_miyoshi.T.molecular_genetic_testing_used_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_miyoshi.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>DYSF</i></td><td headers="hd_h_miyoshi.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for pathogenic variants&#x000a0;<sup>2,&#x000a0;3,&#x000a0;4</sup></td><td headers="hd_h_miyoshi.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">95%</td></tr><tr><td headers="hd_h_miyoshi.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>5</sup></td><td headers="hd_h_miyoshi.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="miyoshi.TF.1.1"><p class="no_margin">See <a href="/books/NBK1303/#miyohsi.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein. See <a href="#miyoshi.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>2. </dt><dd><div id="miyoshi.TF.1.2"><p class="no_margin">Note: Pathogenic variants included in a panel may vary by laboratory.</p></div></dd><dt>3. </dt><dd><div id="miyoshi.TF.1.3"><p class="no_margin">Detects 1624delG <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in Libyan Jews</p></div></dd><dt>4. </dt><dd><div id="miyoshi.TF.1.4"><p class="no_margin">Detects 927delG <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in Jews of the Caucasus [<a class="bk_pop" href="#miyoshi.REF.leshinskysilver.2007.950">Leshinsky-Silver et al 2007</a>]</p></div></dd><dt>5. </dt><dd><div id="miyoshi.TF.1.5"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>6. </dt><dd><div id="miyoshi.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#miyoshi.REF.takahashi.b">Takahashi et al [2003b]</a></p></div></dd></dl></div></div></div></div></div><div id="miyoshi.Testing_Strategy"><h3>Testing Strategy</h3><p><b>To confirm/establish the diagnosis in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Because there are number of conditions that lead to muscle weakness with an elevated CK level, a reasonable approach is to test a muscle biopsy for dysferlin using western immunoblotting. Absence of dysferlin protein almost always indicates a primary dysferlinopathy; however, it is important to note that reduced levels of dysferlin may be secondary to other primary muscular dystrophies [<a class="bk_pop" href="#miyoshi.REF.aoki.2001.271">Aoki et al 2001</a>]. Further <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can then be pursued.</p><p><b>One genetic testing strategy</b> is <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>DYSF</i>, the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which pathogenic variants are known to cause dysferlinopathy.</p><ul><li class="half_rhythm"><div>For individuals of Libyan Jewish ancestry or Jews of the Caucasus, <a class="def" href="/books/n/gene/glossary/def-item/targeted-analysis-for-pathogenic-variants/">targeted analysis for pathogenic variants</a> can be used for confirmation of the diagnosis and <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</div></li><li class="half_rhythm"><div>For individuals of other ethnic backgrounds, <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of the entire <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> can be pursued.</div></li></ul><p><b>An alternative genetic testing strategy</b> is use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that includes <i>DYSF</i> and other genes of interest (see <a href="#miyoshi.Differential_Diagnosis">Differential Diagnosis</a>). Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p></div></div><div id="miyoshi.Clinical_Characteristics"><h2 id="_miyoshi_Clinical_Characteristics_">Clinical Characteristics</h2><div id="miyoshi.Clinical_Description"><h3>Clinical Description</h3><p>Several different clinical presentations have been observed [<a class="bk_pop" href="#miyoshi.REF.ueyama.2002.532">Ueyama et al 2002</a>] and can occur within families having the same pathogenic variants [<a class="bk_pop" href="#miyoshi.REF.liu.1998.31">Liu et al 1998</a>, <a class="bk_pop" href="#miyoshi.REF.weiler.1999.871">Weiler et al 1999</a>, <a class="bk_pop" href="#miyoshi.REF.illarioshkin.2000.1931">Illarioshkin et al 2000</a>, <a class="bk_pop" href="#miyoshi.REF.nakagawa.2001.15">Nakagawa et al 2001</a>, <a class="bk_pop" href="#miyoshi.REF.ueyama.2001.139">Ueyama et al 2001</a>]. The weakness and atrophy may be asymmetric with any of these presentations.</p><p><b>Miyoshi myopathy.</b> Young adults have muscle weakness and atrophy most marked in the distal parts of the legs, especially the gastrocnemius and soleus muscles. Early on, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are not able to stand on tiptoe, but retain the ability to stand on the heels. Over a period of years, the weakness and atrophy spread to the thighs and gluteal muscles, at which time climbing stairs, standing, and walking become difficult. The forearms may become mildly atrophic with decrease in grip strength; the small muscles of the hands are spared. The weakness may eventually include the shoulder girdle muscles [<a class="bk_pop" href="#miyoshi.REF.mahjneh.2001.20">Mahjneh et al 2001</a>].</p><p><b>Limb-girdle muscular dystrophy syndrome.</b> Early weakness and atrophy of the pelvic and shoulder girdle muscles begins in adolescence or young adulthood, with slow progression.</p><p><b>Scapuloperoneal syndrome.</b> Occasionally, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals present with initial weakness of the shoulder girdle muscles combined with distal weakness of the legs.</p><p><b>Distal myopathy with anterior tibial onset.</b> Occasionally, leg weakness may involve the anterior compartment and cause foot drop [<a class="bk_pop" href="#miyoshi.REF.illa.2001.130">Illa et al 2001</a>].</p><p><b>Elevated serum CK concentration only.</b> Some individuals have only a marked elevation of serum CK concentration. This is usually considered a presymptomatic presentation of myopathy in an individual who eventually develops muscle weakness and atrophy. Sometimes the calf muscles are enlarged; this presentation may be confused with a <a href="/books/n/gene/dbmd/">dystrophinopathy</a> (i.e., Duchenne or Becker muscular dystrophy).</p><p><b>Congenital muscular dystrophy.</b> Two sibs with hypotonia beginning between birth and age two months had delayed motor development and serum CK concentrations that were normal or slightly elevated before age three years [<a class="bk_pop" href="#miyoshi.REF.paradas.2009.21">Paradas et al 2009</a>].</p><p>Of 41 Japanese individuals with proven dysferlinopathy, 20 had Miyoshi myopathy and 21 had LGMD2B (<a class="figpopup" href="/books/NBK1303/table/miyoshi.T.comparison_of_miyoshi_myopathy/?report=objectonly" target="object" rid-figpopup="figmiyoshiTcomparisonofmiyoshimyopathy" rid-ob="figobmiyoshiTcomparisonofmiyoshimyopathy">Table 2</a>) [<a class="bk_pop" href="#miyoshi.REF.takahashi.b">Takahashi et al 2003b</a>]. On occasion, both phenotypes can be observed in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sibs [<a class="bk_pop" href="#miyoshi.REF.liu.1998.31">Liu et al 1998</a>].</p><div id="miyoshi.T.comparison_of_miyoshi_myopathy" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Comparison of Miyoshi Myopathy and LGMD2B</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1303/table/miyoshi.T.comparison_of_miyoshi_myopathy/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__miyoshi.T.comparison_of_miyoshi_myopathy_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_miyoshi.T.comparison_of_miyoshi_myopathy_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></th><th id="hd_h_miyoshi.T.comparison_of_miyoshi_myopathy_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Miyoshi Myopathy</th><th id="hd_h_miyoshi.T.comparison_of_miyoshi_myopathy_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">LGMD2B</th></tr></thead><tbody><tr><td headers="hd_h_miyoshi.T.comparison_of_miyoshi_myopathy_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Mean age at onset</b><br /><b>(range)</b></td><td headers="hd_h_miyoshi.T.comparison_of_miyoshi_myopathy_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">21.8 &#x000b1; 7.4 yrs<br />(14-37 yrs)</td><td headers="hd_h_miyoshi.T.comparison_of_miyoshi_myopathy_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">26.2 &#x000b1; 9.2 yrs<br />(14-41 yrs)</td></tr><tr><td headers="hd_h_miyoshi.T.comparison_of_miyoshi_myopathy_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Average age of using a cane</b><br /><b>(yrs after onset)</b></td><td headers="hd_h_miyoshi.T.comparison_of_miyoshi_myopathy_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">35.5 yrs<br />(16 yrs)</td><td headers="hd_h_miyoshi.T.comparison_of_miyoshi_myopathy_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">39.3 yrs<br />(13.6 yrs)</td></tr><tr><td headers="hd_h_miyoshi.T.comparison_of_miyoshi_myopathy_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Age at which wheelchair-bound</b><br /><b>(yrs after onset)</b></td><td headers="hd_h_miyoshi.T.comparison_of_miyoshi_myopathy_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">42.8 yrs<br />(22.8 yrs)</td><td headers="hd_h_miyoshi.T.comparison_of_miyoshi_myopathy_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">45.1 yrs<br />(21.4 yrs)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin"><a class="bk_pop" href="#miyoshi.REF.takahashi.b">Takahashi et al [2003b]</a></p></div></dd></dl></div></div></div></div><div id="miyoshi.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>One study reported that the 3370G&#x0003e;T <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was associated with a milder form of Miyoshi myopathy and the 3510G&#x0003e;A pathogenic variant was associated with a more severe form [<a class="bk_pop" href="#miyoshi.REF.takahashi.2003a.1799">Takahashi et al 2003a</a>, <a class="bk_pop" href="#miyoshi.REF.takahashi.2013.433">Takahashi et al 2013</a>].</p></div><div id="miyoshi.Nomenclature"><h3>Nomenclature</h3><p>Dysferlinopathy was originally called LGMD2B because at the time that it was mapped to 2p13 it was the second form (2) of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> (B) limb-girdle muscular dystrophy (LGMD) to be mapped. The <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> for Miyoshi myopathy and the gene for LGMD2B were mapped to the same genetic interval at <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 2p13. Two groups independently identified a novel human skeletal muscle gene, <i>DYSF</i>, at this <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and documented that <i>DYSF</i> pathogenic variants cause both Miyoshi myopathy and LGMD2B.</p></div><div id="miyoshi.Prevalence"><h3>Prevalence</h3><p>The prevalence is not known. In the initial (1967) description of Miyoshi myopathy, 50 out of 72 families were from Japan. <a class="bk_pop" href="#miyoshi.REF.tagawa.2003.23">Tagawa et al [2003]</a> examined a total of 107 unrelated Japanese individuals, including 53 with unclassified LGMD, 28 with Miyoshi myopathy, and 26 with other neuromuscular disorders. Expression of dysferlin protein was observed using immunohistochemistry (IHC) and mini-multiplex western blotting (MMW). They found a deficiency of dysferlin protein by using both IHC and MMW in 19% of individuals with LGMD and 75% of individuals with Miyoshi myopathy.</p><p>In Libyan Jews, the prevalence is at least one per 1,300, with a <a class="def" href="/books/n/gene/glossary/def-item/carrier-rate/">carrier rate</a> of approximately 10% [<a class="bk_pop" href="#miyoshi.REF.argov.2000.1229">Argov et al 2000</a>].</p><p>A <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> (Arg1905Ter) has been reported in Spain [<a class="bk_pop" href="#miyoshi.REF.vilchez.2005.1256">Vilchez et al 2005</a>].</p></div></div><div id="miyoshi.Genetically_Related_Allelic_Diso"><h2 id="_miyoshi_Genetically_Related_Allelic_Diso_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> have been associated with mutation of <i>DYSF</i>.</p></div><div id="miyoshi.Differential_Diagnosis"><h2 id="_miyoshi_Differential_Diagnosis_">Differential Diagnosis</h2><p>Dysferlinopathy needs to be distinguished from other <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> limb-girdle muscular dystrophies.</p><p>Individuals with LGMD generally show weakness and wasting restricted to the limb musculature, proximal greater than distal. Most individuals with LGMD show relative sparing of the heart and bulbar muscles, although exceptions occur, depending on the genetic subtype. Onset, progression, and distribution of the weakness and wasting vary considerably among individuals and genetic subtypes.</p><p>The limb-girdle muscular dystrophies typically show degeneration/regeneration of muscle (dystrophic biopsy), which is usually associated with elevated serum creatine kinase concentration. Biochemical testing (i.e., protein testing by immunostaining) performed on a muscle biopsy can establish the diagnosis of the LGMD subtypes sarcoglycanopathy (OMIM <a href="http://omim.org/entry/608099" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">608099</a> and <a href="http://omim.org/entry/604286" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">604286</a>), <a href="/books/n/gene/lgmd2a/">calpainopathy</a>, and dysferlinopathy. In some cases, demonstration of complete or partial deficiencies for any particular protein can then be followed by molecular genetic studies of the corresponding <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p><p>The caveolinopathies are a group of muscle diseases caused by pathogenic variants in <i>CAV3</i>, which encodes caveolin-3 (OMIM <a href="https://omim.org/entry/601253" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">601253</a>), a muscle-specific membrane protein and the principal component of caveolae membrane in muscle cells in vivo. The caveolinopathies, which are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner, can be classified into five phenotypes:</p><ul><li class="half_rhythm"><div>Limb-girdle muscular dystrophy 1C (LGMD1C) characterized by onset usually in the first decade, mild-to-moderate proximal muscle weakness, calf hypertrophy, positive Gower sign, and variable muscle cramps after exercise;</div></li><li class="half_rhythm"><div>Isolated hyperCKemia (i.e., elevated serum concentration of creatine kinase (CK) in the absence of signs of muscle disease) (HCK);</div></li><li class="half_rhythm"><div>Rippling muscle disease (RMD), characterized by signs of increased muscle irritability, such as percussion-induced rapid contraction (PIRC), percussion-induced muscle mounding (PIMM), and/or electrically silent muscle contractions (rippling muscle);</div></li><li class="half_rhythm"><div>Distal myopathy (DM), observed in one individual only;</div></li><li class="half_rhythm"><div>Hypertrophic cardiomyopathy (HCM), without skeletal muscle manifestations.</div></li></ul><p>The differential diagnosis also includes the <a href="/books/n/gene/dbmd/">dystrophinopathies</a> (Duchenne/Becker muscular dystrophy), polymyositis, and distal myopathies [<a class="bk_pop" href="#miyoshi.REF.udd.2001.561">Udd &#x00026; Griggs 2001</a>].</p><p>Other distal myopathies have been identified with clinical and genetic patterns as follows (see <a class="figpopup" href="/books/NBK1303/table/miyoshi.T.distal_myopathies/?report=objectonly" target="object" rid-figpopup="figmiyoshiTdistalmyopathies" rid-ob="figobmiyoshiTdistalmyopathies">Table 3</a>).</p><div id="miyoshi.T.distal_myopathies" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Distal Myopathies</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1303/table/miyoshi.T.distal_myopathies/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__miyoshi.T.distal_myopathies_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_miyoshi.T.distal_myopathies_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Disease Name</th><th id="hd_h_miyoshi.T.distal_myopathies_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mean Age at Onset</th><th id="hd_h_miyoshi.T.distal_myopathies_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Initial Muscle Group Involved</th><th id="hd_h_miyoshi.T.distal_myopathies_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Serum Creatine Kinase Concentration</th><th id="hd_h_miyoshi.T.distal_myopathies_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Muscle Biopsy</th><th id="hd_h_miyoshi.T.distal_myopathies_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene (Locus)&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_1 hd_h_miyoshi.T.distal_myopathies_1_1_1_2 hd_h_miyoshi.T.distal_myopathies_1_1_1_3 hd_h_miyoshi.T.distal_myopathies_1_1_1_4 hd_h_miyoshi.T.distal_myopathies_1_1_1_5 hd_h_miyoshi.T.distal_myopathies_1_1_1_6" colspan="6" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Autosomal Dominant</b></td></tr><tr><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Welander distal myopathy (OMIM <a href="http://omim.org/entry/604454" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">604454</a>)</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;40 years</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distal upper limbs (finger &#x00026; wrist extensors)</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_4" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;">Normal or slightly increased</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rimmed vacuoles</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(2p13)</td></tr><tr><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/udd/">Udd distal myopathy</a></td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;35</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Anterior compartment in legs</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_5" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">&#x000b1; Rimmed vacuoles</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TTN</i></td></tr><tr><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Zaspopathy (Markesbery-Griggs late-onset distal myopathy) (OMIM <a href="https://omim.org/entry/609452" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">609452</a>)</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;40</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_5" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Vacuolar &#x00026; myofibrillar myopathy</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>LDB3</i></td></tr><tr><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distal myotilinopathy (OMIM <a href="https://omim.org/entry/609200" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">609200</a>)</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;40</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Posterior &#x0003e; anterior in legs</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Slightly increased</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Vacuolar &#x00026; myofibrillar myopathy</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MYOT</i></td></tr><tr><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/mpd1/">Laing early-onset distal myopathy</a> (MPD1)</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;20</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Anterior compartment in legs &#x00026; neck flexors</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Moderately increased</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Type 1 fiber atrophy in tibial anterior muscles; disproportion in proximal muscles</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MYH7</i></td></tr><tr><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distal myopathy with vocal cord and pharyngeal signs (MPD2)</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">35-60</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Asymmetric lower leg &#x00026; hands; dysphonia</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1-8 times</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rimmed vacuoles</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(5q)</td></tr><tr><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distal myopathy with <i>pes cavus</i> and areflexia</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15-50</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Anterior &#x00026; posterior lower leg; dysphonia and dysphagia</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2-6 times</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dystrophic, rimmed vacuoles</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(19p13)</td></tr><tr><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">New Finnish distal myopathy (MPD3)</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;30</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hands or anterior lower leg</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1-4 times</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dystrophic; rimmed vacuoles; eosinophilic inclusions</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(8p22-q11 and 12q13-q22)</td></tr><tr><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_1 hd_h_miyoshi.T.distal_myopathies_1_1_1_2 hd_h_miyoshi.T.distal_myopathies_1_1_1_3 hd_h_miyoshi.T.distal_myopathies_1_1_1_4 hd_h_miyoshi.T.distal_myopathies_1_1_1_5 hd_h_miyoshi.T.distal_myopathies_1_1_1_6" colspan="6" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Autosomal Recessive</b></td></tr><tr><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/ibm/">Nonaka early-adult-onset distal myopathy</a></td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">15-20</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Anterior compartment in legs</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;10 times</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rimmed vacuoles</td><td headers="hd_h_miyoshi.T.distal_myopathies_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GNE</i></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin"><a class="bk_pop" href="#miyoshi.REF.udd.2001.561">Udd &#x00026; Griggs [2001]</a></p></div></dd><dt>1. </dt><dd><div id="miyoshi.TF.3.1"><p class="no_margin">Locus given only if the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> is not known</p></div></dd></dl></div></div></div></div><div id="miyoshi.Management"><h2 id="_miyoshi_Management_">Management</h2><div id="miyoshi.Evaluations_Following_Initial_Di"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with dysferlinopathy, the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Assessment of strength and function in the arms, hands, legs, and feet; especially calf muscle</div></li><li class="half_rhythm"><div>If needed, measurement of serum CK concentration</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="miyoshi.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>No definitive treatments exist for the limb-girdle muscular dystrophies.</p><p>Management should be tailored to each individual and each specific subtype. A general approach to appropriate management can prolong survival and improve quality of life. This general approach is based on the typical progression and complications of individuals with LGMD as described by <a class="bk_pop" href="#miyoshi.REF.mcdonald.1995.s117">McDonald et al [1995]</a> and <a class="bk_pop" href="#miyoshi.REF.bushby.1999.1403">Bushby [1999]</a>.</p><ul><li class="half_rhythm"><div>Physical therapy and stretching exercises to promote mobility and prevent contractures</div></li><li class="half_rhythm"><div>Use of mechanical aids such as canes, walkers, orthotics, and wheelchairs as needed to help ambulation and mobility</div></li><li class="half_rhythm"><div>Surgical intervention as needed for orthopedic complications such as foot deformity and scoliosis</div></li><li class="half_rhythm"><div>Use of respiratory aids when indicated</div></li><li class="half_rhythm"><div>Social and emotional support and stimulation to maximize a sense of social involvement and productivity and to reduce the sense of social isolation common in these disorders</div></li></ul></div><div id="miyoshi.Prevention_of_Secondary_Complica"><h3>Prevention of Secondary Complications</h3><p>Stretching exercises to prevent contractures are indicated.</p></div><div id="miyoshi.Surveillance"><h3>Surveillance</h3><p>The following surveillance is appropriate:</p><ul><li class="half_rhythm"><div>Annual monitoring of muscle strength, joint range of motion, and respiratory function</div></li><li class="half_rhythm"><div>Monitoring for evidence of cardiomyopathy in those subtypes with known occurrence of cardiac involvement</div></li></ul></div><div id="miyoshi.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Control weight to avoid obesity; avoid use of steroids [<a class="bk_pop" href="#miyoshi.REF.walter.2013.26">Walter et al 2013</a>].</p></div><div id="miyoshi.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#miyoshi.Related_Genetic_Counseling_Issue">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="miyoshi.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>A double-blinded, placebo-controlled clinical trial of deflazacort in individuals with genetically confirmed dysferlinopathy has been completed [<a class="bk_pop" href="#miyoshi.REF.walter.2013.26">Walter et al 2013</a>]. After six months of treatment, muscle strength did not improve; rather, there was a trend towards worsening muscle strength for <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals on deflazacort treatment. Muscle strength improved after the study drug was discontinued. Side effects included a broad spectrum typically seen in those taking steroids. Therefore, deflazacort treatment is not effective as a therapy for individuals with dysferlinopathies; additionally, the authors concluded that steroid treatment in general should be avoided in this condition [<a class="bk_pop" href="#miyoshi.REF.walter.2013.26">Walter et al 2013</a>].</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="miyoshi.Genetic_Counseling"><h2 id="_miyoshi_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="miyoshi.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Dysferlinopathy is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="miyoshi.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual are obligate heterozygotes and therefore carry one <i>DYSF</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Once an at-risk sib is known to be unaffected, the risk of his/her being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>DYSF</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is 2/3.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with dysferlinopathy are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>DYSF</i>.</p><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each sib of the proband's parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>DYSF</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="miyoshi.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>DYSF</i> pathogenic variants in the family.</p></div><div id="miyoshi.Related_Genetic_Counseling_Issue"><h3>Related Genetic Counseling Issues</h3><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="miyoshi.Prenatal_Testing_and_Preimplanta"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>DYSF</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="miyoshi.Resources"><h2 id="_miyoshi_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Jain Foundation Inc.</b></div><div><i>The Jain Foundation is a non-profit foundation whose mission is to diagnose and cure limb girdle muscular dystrophies caused by dysferlin protein deficiency (LGMD2B/Miyoshi Myopathy).</i></div><div>2310 130th Avenue Northeast</div><div>Suite B101</div><div>Bellevue WA 98005</div><div><b>Phone:</b> 425-882-1440</div><div><b>Email:</b> ehwang@jain-foundation.org</div><div><a href="http://www.jain-foundation.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.jain-foundation.org</a></div></li><li class="half_rhythm"><div><b>Muscular Dystrophy Association - USA (MDA)</b></div><div>222 South Riverside Plaza</div><div>Suite 1500</div><div>Chicago IL 60606</div><div><b>Phone:</b> 800-572-1717</div><div><b>Email:</b> mda@mdausa.org</div><div><a href="http://www.mda.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mda.org</a></div></li><li class="half_rhythm"><div><b>Muscular Dystrophy UK</b></div><div>61A Great Suffolk Street</div><div>London SE1 0BU </div><div>United Kingdom</div><div><b>Phone:</b> 0800 652 6352 (toll-free); 020 7803 4800</div><div><b>Email:</b> info@musculardystrophyuk.org</div><div><a href="http://www.musculardystrophyuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.musculardystrophyuk.org</a></div></li></ul></div><div id="miyoshi.Molecular_Genetics"><h2 id="_miyoshi_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="miyoshi.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Dysferlinopathy: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1303/table/miyoshi.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__miyoshi.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_miyoshi.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Locus Name</th><th id="hd_b_miyoshi.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_miyoshi.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_miyoshi.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_miyoshi.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_miyoshi.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_miyoshi.molgen.TA_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_miyoshi.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">LGMD2B</td><td headers="hd_b_miyoshi.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/8291" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>DYSF</i></a></td><td headers="hd_b_miyoshi.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=8291" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">2p13<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_miyoshi.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/O75923" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Dysferlin</a></td><td headers="hd_b_miyoshi.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://databases.lovd.nl/shared/genes/DYSF" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DYSF homepage - Leiden Muscular Dystrophy pages</a></td><td headers="hd_b_miyoshi.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=DYSF" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DYSF</a></td><td headers="hd_b_miyoshi.molgen.TA_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=DYSF[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">DYSF</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="miyoshi.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="miyoshi.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Dysferlinopathy (<a href="/omim/253601,254130,603009" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1303/table/miyoshi.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__miyoshi.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/253601" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">253601</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 2; LGMDR2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/254130" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">254130</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MIYOSHI MUSCULAR DYSTROPHY 1; MMD1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/603009" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">603009</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DYSFERLIN; DYSF</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>DYS</i> has 55 exons and 6,243 base-pair nucleotides in an <a class="def" href="/books/n/gene/glossary/def-item/open-reading-frame/">open reading frame</a> predicted to encode a protein of 2,080 amino acids. Recently, novel dysferlin transcripts were characterized by identifying alternative exons 1 of DYSF-v1 (GenBank DQ267935), <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 5a (GenBank DQ976379), and exon 40a (GenBank EF015906), although no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was identified in alternative exons [<a class="bk_pop" href="#miyoshi.REF.krahn.2009.439">Krahn et al 2009</a>]. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1303/#miyoshi.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b>
<a class="bk_pop" href="#miyoshi.REF.argov.2000.1229">Argov et al [2000]</a> identified the 1624delG <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in 12 Libyan Jewish families with LGMD2B. Among Japanese individuals with Miyoshi myopathy, four pathogenic variants (1939C&#x0003e;G, 3370G&#x0003e;T, 3746delG, and 4870delT) account for 60% of all pathogenic variants [<a class="bk_pop" href="#miyoshi.REF.takahashi.2003a.1799">Takahashi et al 2003a</a>]. The possible existence of a <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a> for the 2785C&#x0003e;T pathogenic variant in the Italian population was reported [<a class="bk_pop" href="#miyoshi.REF.cagliani.2003.788">Cagliani et al 2003</a>]. Many pathogenic variants have been observed in individuals of various ethnic origins. These pathogenic variants were widely spread throughout the coding sequence of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> without any mutational "<a class="def" href="/books/n/gene/glossary/def-item/hot-spot/">hot spot</a>" [<a class="bk_pop" href="#miyoshi.REF.cagliani.2005.283">Cagliani et al 2005</a>, <a class="bk_pop" href="#miyoshi.REF.nguyen.2005.165">Nguyen et al 2005</a>, <a class="bk_pop" href="#miyoshi.REF.krahn.2009.439">Krahn et al 2009</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Antibodies to dysferlin identify a protein of approximately 230 kd and show that dysferlin is located in the muscle membrane [<a class="bk_pop" href="#miyoshi.REF.anderson.1999.855">Anderson et al 1999</a>, <a class="bk_pop" href="#miyoshi.REF.matsuda.1999.1119">Matsuda et al 1999</a>]. Although the function of dysferlin is as yet unknown, dysferlin includes C2 domains thought to be important for calcium-mediated membrane fusion, and dysferlin was reported to have an essential role in the calcium-dependent membrane repair of skeletal muscle fibers [<a class="bk_pop" href="#miyoshi.REF.bansal.2003.168">Bansal et al 2003</a>, <a class="bk_pop" href="#miyoshi.REF.bansal.2004.206">Bansal &#x00026; Campbell 2004</a>].</p><p><a class="bk_pop" href="#miyoshi.REF.matsuda.2001.1761">Matsuda et al [2001]</a> reported a possible interaction between dysferlin and caveolin-3 to subserve signaling functions of caveolae. <a class="bk_pop" href="#miyoshi.REF.lennon.2003.50466">Lennon et al [2003]</a> reported an interaction between dysferlin and phospholipid- and calcium-binding annexins and suggested a role for annexins A1 and A2 in vesicle fusion during dysferlin-mediated membrane repair. <a class="bk_pop" href="#miyoshi.REF.matsuda.2005.334">Matsuda et al [2005]</a> reported that affixin (beta-parvin), a novel, integrin-linked kinase-binding protein, is a dysferlin-binding protein that colocalizes with dysferlin at the sarcolemma of normal human skeletal muscle. The immunoreactivity of affixin was reduced in sarcolemma of Miyoshi myopathy and LGMD2B muscles, although the total amount of affixin protein was normal.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> While no correlations between <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> type and <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> have been found, the 3510G&#x0003e;A pathogenic variant associated with the severe form of Miyoshi myopathy is located around a region of relative hydrophilia. <a class="bk_pop" href="#miyoshi.REF.takahashi.2003a.1799">Takahashi et al [2003a]</a> speculate that this hydrophilic region may be important for the function of the protein.</p><p>Disruption of the muscle membrane repair machinery is responsible for dysferlin-deficient muscle degeneration in dysferlin-null mice [<a class="bk_pop" href="#miyoshi.REF.bansal.2003.168">Bansal et al 2003</a>, <a class="bk_pop" href="#miyoshi.REF.bansal.2004.206">Bansal &#x00026; Campbell 2004</a>]. <a class="bk_pop" href="#miyoshi.REF.cenacchi.2005.190">Cenacchi et al [2005]</a> reported that histopathologic, immunohistochemical, and ultrastructural analyses show muscle with dysferlinopathy to be characterized by a very active inflammatory/degenerative process, possibly associated with an inefficient repair and regenerative system.</p></div><div id="miyoshi.References"><h2 id="_miyoshi_References_">References</h2><div id="miyoshi.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.anderson.1999.855">Anderson LV, Davison K, Moss JA, Young C, Cullen MJ, Walsh J, Johnson MA, Bashir R, Britton S, Keers S, Argov Z, Mahjneh I, Fougerousse F, Beckmann JS, Bushby KM. Dysferlin is a plasma membrane protein and is expressed early in human development. <span><span class="ref-journal">Hum Mol Genet. </span>1999;<span class="ref-vol">8</span>:855–61.</span> [<a href="/pubmed/10196375" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10196375</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.ankala.2014.333">Ankala A, Nallamilli BR, Rufibach LE, Hwang E, Hegde MR. Diagnostic overview of blood-based dysferlin protein assay for dysferlinopathies. <span><span class="ref-journal">Muscle Nerve. </span>2014;<span class="ref-vol">50</span>:333–9.</span> [<a href="/pubmed/24488599" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24488599</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.aoki.2001.271">Aoki M, Liu J, Richard I, Bashir R, Britton S, Keers SM, Oeltjen J, Brown HE, Marchand S, Bourg N, Beley C, McKenna-Yasek D, Arahata K, Bohlega S, Cupler E, Illa I, Majneh I, Barohn RJ, Urtizberea JA, Fardeau M, Amato A, Angelini C, Bushby K, Beckmann JS, Brown RH Jr. Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy. <span><span class="ref-journal">Neurology. </span>2001;<span class="ref-vol">57</span>:271–8.</span> [<a href="/pubmed/11468312" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11468312</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.argov.2000.1229">Argov Z, Sadeh M, Mazor K, Soffer D, Kahana E, Eisenberg I, Mitrani-Rosenbaum S, Richard I, Beckmann J, Keers S, Bashir R, Bushby K, Rosenmann H. Muscular dystrophy due to dysferlin deficiency in Libyan Jews. Clinical and genetic features. <span><span class="ref-journal">Brain. </span>2000;<span class="ref-vol">123</span>:1229–37.</span> [<a href="/pubmed/10825360" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10825360</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.bansal.2004.206">Bansal D, Campbell KP. Dysferlin and the plasma membrane repair in muscular dystrophy. <span><span class="ref-journal">Trends Cell Biol. </span>2004;<span class="ref-vol">14</span>:206–13.</span> [<a href="/pubmed/15066638" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15066638</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.bansal.2003.168">Bansal D, Miyake K, Vogel SS, Groh S, Chen CC, Williamson R, McNeil PL, Campbell KP. Defective membrane repair in dysferlin-deficient muscular dystrophy. <span><span class="ref-journal">Nature. </span>2003;<span class="ref-vol">423</span>:168–72.</span> [<a href="/pubmed/12736685" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12736685</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.bushby.1999.1403">Bushby KM. Making sense of the limb-girdle muscular dystrophies. <span><span class="ref-journal">Brain. </span>1999;<span class="ref-vol">122</span>:1403–20.</span> [<a href="/pubmed/10430828" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10430828</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.cagliani.2003.788">Cagliani R, Fortunato F, Giorda R, Rodolico C, Bonaglia MC, Sironi M, D'Angelo MG, Prelle A, Locatelli F, Toscano A, Bresolin N, Comi GP. Molecular analysis of LGMD-2B and MM patients: identification of novel DYSF mutations and possible founder effect in the Italian population. <span><span class="ref-journal">Neuromuscul Disord. </span>2003;<span class="ref-vol">13</span>:788–95.</span> [<a href="/pubmed/14678801" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14678801</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.cagliani.2005.283">Cagliani R, Magri F, Toscano A, Merlini L, Fortunato F, Lamperti C, Rodolico C, Prelle A, Sironi M, Aguennouz M, Ciscato P, Uncini A, Moggio M, Bresolin N, Comi GP. Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dystrophies. <span><span class="ref-journal">Hum Mutat. </span>2005;<span class="ref-vol">26</span>:283.</span> [<a href="/pubmed/16100712" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16100712</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.cenacchi.2005.190">Cenacchi G, Fanin M, De Giorgi LB, Angelini C. Ultrastructural changes in dysferlinopathy support defective membrane repair mechanism. <span><span class="ref-journal">J Clin Pathol. </span>2005;<span class="ref-vol">58</span>:190–5.</span> [<a href="/pmc/articles/PMC1770568/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1770568</span></a>] [<a href="/pubmed/15677541" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15677541</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.eymard.2000.161">Eymard B, Laforet P, Tome FM, Collin H, Leroy JP, Hauw JJ, Richard I, Beckmann J, Fardeau M. <span><span class="ref-journal">Rev Neurol (Paris). </span>2000;<span class="ref-vol">156</span>:161–8.</span> [Miyoshi distal myopathy: specific signs and incidence] [<a href="/pubmed/10743015" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10743015</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.fanin.2002.461">Fanin M, Angelini C. Muscle pathology in dysferlin deficiency. <span><span class="ref-journal">Neuropathol Appl Neurobiol. </span>2002;<span class="ref-vol">28</span>:461–70.</span> [<a href="/pubmed/12445162" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12445162</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.gallardo.2001.2136">Gallardo E, Rojas-Garcia R, de Luna N, Pou A, Brown RH Jr, Illa I. Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. <span><span class="ref-journal">Neurology. </span>2001;<span class="ref-vol">57</span>:2136–8.</span> [<a href="/pubmed/11739845" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11739845</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.ho.2002.129">Ho M, Gallardo E, McKenna-Yasek D, De Luna N, Illa I, Brown RH Jr. A novel, blood-based diagnostic assay for limb girdle muscular dystrophy 2B and Miyoshi myopathy. <span><span class="ref-journal">Ann Neurol. </span>2002;<span class="ref-vol">51</span>:129–33.</span> [<a href="/pubmed/11782994" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11782994</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.illa.2001.130">Illa I, Serrano-Munuera C, Gallardo E, Lasa A, Rojas-Garcia R, Palmer J, Gallano P, Baiget M, Matsuda C, Brown RH. Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. <span><span class="ref-journal">Ann Neurol. </span>2001;<span class="ref-vol">49</span>:130–4.</span> [<a href="/pubmed/11198284" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11198284</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.illarioshkin.2000.1931">Illarioshkin SN, Ivanova-Smolenskaya IA, Greenberg CR, Nylen E, Sukhorukov VS, Poleshchuk VV, Markova ED, Wrogemann K. Identical dysferlin mutation in limb-girdle muscular dystrophy type 2B and distal myopathy. <span><span class="ref-journal">Neurology. </span>2000;<span class="ref-vol">55</span>:1931–3.</span> [<a href="/pubmed/11134403" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11134403</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.krahn.2009.439">Krahn M, Borges A, Navarro C, Schuit R, Stojkovic T, Torrente Y, Wein N, P&#x000e9;cheux C, L&#x000e9;vy N. Identification of different genomic deletions and one duplication in the dysferlin gene using multiplex ligation-dependent probe amplification and genomic quantitative PCR. <span><span class="ref-journal">Genet Test Mol Biomarkers. </span>2009;<span class="ref-vol">13</span>:439–42.</span> [<a href="/pubmed/19594366" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19594366</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.lennon.2003.50466">Lennon NJ, Kho A, Bacskai BJ, Perlmutter SL, Hyman BT, Brown RH Jr. Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. <span><span class="ref-journal">J Biol Chem. </span>2003;<span class="ref-vol">278</span>:50466–73.</span> [<a href="/pubmed/14506282" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14506282</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.leshinskysilver.2007.950">Leshinsky-Silver E, Argov Z, Rozenboim L, Cohen S, Tzofi Z, Cohen Y, Wirguin Y, Dabby R, Lev D, Sadeh M. Dysferlinopathy in the Jews of the Caucasus: a frequent mutation in the dysferlin gene. <span><span class="ref-journal">Neuromuscul Disord. </span>2007;<span class="ref-vol">17</span>:950–4.</span> [<a href="/pubmed/17825554" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17825554</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.liu.1998.31">Liu J, Aoki M, Illa I, Wu C, Fardeau M, Angelini C, Serrano C, Urtizberea JA, Hentati F, Hamida MB, Bohlega S, Culper EJ, Amato AA, Bossie K, Oeltjen J, Bejaoui K, McKenna-Yasek D, Hosler BA, Schurr E, Arahata K, de Jong PJ, Brown RH Jr. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. <span><span class="ref-journal">Nat Genet. </span>1998;<span class="ref-vol">20</span>:31–6.</span> [<a href="/pubmed/9731526" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9731526</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.mahjneh.2001.20">Mahjneh I, Marconi G, Bushby K, Anderson LV, Tolvanen-Mahjneh H, Somer H. Dysferlinopathy (LGMD2B): a 23-year follow-up study of 10 patients homozygous for the same frameshifting dysferlin mutations. <span><span class="ref-journal">Neuromuscul Disord. </span>2001;<span class="ref-vol">11</span>:20–6.</span> [<a href="/pubmed/11166162" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11166162</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.matsuda.1999.1119">Matsuda C, Aoki M, Hayashi YK, Ho MF, Arahata K, Brown RH Jr. Dysferlin is a surface membrane-associated protein that is absent in Miyoshi myopathy. <span><span class="ref-journal">Neurology. </span>1999;<span class="ref-vol">53</span>:1119–22.</span> [<a href="/pubmed/10496277" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10496277</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.matsuda.2001.1761">Matsuda C, Hayashi YK, Ogawa M, Aoki M, Murayama K, Nishino I, Nonaka I, Arahata K, Brown RH Jr. The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle. <span><span class="ref-journal">Hum Mol Genet. </span>2001;<span class="ref-vol">10</span>:1761–6.</span> [<a href="/pubmed/11532985" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11532985</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.matsuda.2005.334">Matsuda C, Kameyama K, Tagawa K, Ogawa M, Suzuki A, Yamaji S, Okamoto H, Nishino I, Hayashi YK. Dysferlin interacts with affixin (beta-parvin) at the sarcolemma. <span><span class="ref-journal">J Neuropathol Exp Neurol. </span>2005;<span class="ref-vol">64</span>:334–40.</span> [<a href="/pubmed/15835269" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15835269</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.mcdonald.1995.s117">McDonald CM, Johnson ER, Abresch RT, Carter GT, Fowler WM Jr, Kilmer DD. Profiles of neuromuscular diseases. Limb-girdle syndromes. <span><span class="ref-journal">Am J Phys Med Rehabil. </span>1995;<span class="ref-vol">74</span>:S117–30.</span> [<a href="/pubmed/7576419" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7576419</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.nakagawa.2001.15">Nakagawa M, Matsuzaki T, Suehara M, Kanzato N, Takashima H, Higuchi I, Matsumura T, Goto K, Arahata K, Osame M. Phenotypic variation in a large Japanese family with Miyoshi myopathy with nonsense mutation in exon 19 of dysferlin gene. <span><span class="ref-journal">J Neurol Sci. </span>2001;<span class="ref-vol">184</span>:15–9.</span> [<a href="/pubmed/11231027" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11231027</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.nguyen.2005.165">Nguyen K, Bassez G, Bernard R, Krahn M, Labelle V, Figarella-Branger D, Pouget J, Hammouda EH, B&#x000e9;roud C, Urtizberea A, Eymard B, Leturcq F, L&#x000e9;vy N. Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies. <span><span class="ref-journal">Hum Mutat. </span>2005;<span class="ref-vol">26</span>:165.</span> [<a href="/pubmed/16010686" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16010686</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.paradas.2009.21">Paradas C, Gonz&#x000e1;lez-Quereda L, De Luna N, Gallardo E, Garc&#x000ed;a-Consuegra I, G&#x000f3;mez H, Cabello A, Illa I, Gallano P. A new phenotype of dysferlinopathy with congenital onset. <span><span class="ref-journal">Neuromuscul Disord. </span>2009;<span class="ref-vol">19</span>:21–5.</span> [<a href="/pubmed/19084402" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19084402</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.piccolo.2000.902">Piccolo F, Moore SA, Ford GC, Campbell KP. Intracellular accumulation and reduced sarcolemmal expression of dysferlin in limb-girdle muscular dystrophies. <span><span class="ref-journal">Ann Neurol. </span>2000;<span class="ref-vol">48</span>:902–12.</span> [<a href="/pubmed/11117547" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11117547</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.prelle.2003.537">Prelle A, Sciacco M, Tancredi L, Fagiolari G, Comi GP, Ciscato P, Serafini M, Fortunato F, Zecca C, Gallanti A, Chiveri L, Bresolin N, Scarlato G, Moggio M. Clinical, morphological and immunological evaluation of six patients with dysferlin deficiency. <span><span class="ref-journal">Acta Neuropathol (Berl). </span>2003;<span class="ref-vol">105</span>:537–42.</span> [<a href="/pubmed/12734659" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12734659</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.saito.2002.615">Saito A, Higuchi I, Nakagawa M, Saito M, Hirata K, Suehara M, Yoshida Y, Takahashi T, Aoki M, Osame M. Miyoshi myopathy patients with novel 5' splicing donor site mutations showed different dysferlin immunostaining at the sarcolemma. <span><span class="ref-journal">Acta Neuropathol (Berl). </span>2002;<span class="ref-vol">104</span>:615–20.</span> [<a href="/pubmed/12410383" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12410383</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.serratrice.2002.1025">Serratrice G, Pellissier JF, N'Guyen V, Attarian S, Pouget J. Dysferlinopathy. Example of a new myopathy. <span><span class="ref-journal">Bull Acad Natl Med. </span>2002;<span class="ref-vol">186</span>:1025–32.</span> [<a href="/pubmed/12587341" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12587341</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.tagawa.2003.23">Tagawa K, Ogawa M, Kawabe K, Yamanaka G, Matsumura T, Goto K, Nonaka I, Nishino I, Hayashi YK. Protein and gene analyses of dysferlinopathy in a large group of Japanese muscular dystrophy patients. <span><span class="ref-journal">J Neurol Sci. </span>2003;<span class="ref-vol">211</span>:23–8.</span> [<a href="/pubmed/12767493" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12767493</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.takahashi.2013.433">Takahashi T, Aoki M, Suzuki N, Tateyama M, Yaginuma C, Sato H, Hayasaka M, Sugawara H, Ito M, Abe-Kondo E, Shimakura N, Ibi T, Kuru S, Wakayama T, Sobue G, Fujii N, Saito T, Matsumura T, Funakawa I, Mukai E, Kawanami T, Morita M, Yamazaki M, Hasegawa T, Shimizu J, Tsuji S, Kuzuhara S, Tanaka H, Yoshioka M, Konno H, Onodera H, Itoyama Y. Clinical features and a mutation with late onset of limb girdle muscular dystrophy 2B. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2013;<span class="ref-vol">84</span>:433–40.</span> [<a href="/pmc/articles/PMC3595148/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3595148</span></a>] [<a href="/pubmed/23243261" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23243261</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.takahashi.2003a.1799">Takahashi T, Aoki M, Tateyama M, Kondo E, Mizuno T, Onodera Y, Takano R, Kawai H, Kamakura K, Mochizuki H, Shizuka-Ikeda M, Nakagawa M, Yoshida Y, Akanuma J, Hoshino K, Saito H, Nishizawa M, Kato S, Saito K, Miyachi T, Yamashita H, Kawai M, Matsumura T, Kuzuhara S, Ibi T, Sahashi K, Nakai H, Kohnosu T, Nonaka I, Arahata K, Brown RH Jr, Saito H, Itoyama Y. Dysferlin mutations in Japanese Miyoshi myopathy: Relationship to phenotype. <span><span class="ref-journal">Neurology. </span>2003a;<span class="ref-vol">60</span>:1799–804.</span> [<a href="/pubmed/12796534" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12796534</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.takahashi.b">Takahashi T, Aoki M, Tateyama M, Onodera Y, Kondo E, Sato H, Ito M, Yoshioka M, Konno K, Brown RH Jr, Saito H, Itoyama Y (2003b) Mutational and clinical features of Japanese patients with dysferlinopathy. Neurology 60 Suppl A:233.</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.udd.2001.561">Udd B, Griggs R. Distal myopathies. <span><span class="ref-journal">Curr Opin Neurol. </span>2001;<span class="ref-vol">14</span>:561–6.</span> [<a href="/pubmed/11562566" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11562566</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.ueyama.2002.532">Ueyama H, Kumamoto T, Horinouchi H, Fujimoto S, Aono H, Tsuda T. Clinical heterogeneity in dysferlinopathy. <span><span class="ref-journal">Intern Med. </span>2002;<span class="ref-vol">41</span>:532–6.</span> [<a href="/pubmed/12132520" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12132520</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.ueyama.2001.139">Ueyama H, Kumamoto T, Nagao S, Masuda T, Horinouchi H, Fujimoto S, Tsuda T. A new dysferlin gene mutation in two Japanese families with limb-girdle muscular dystrophy 2B and Miyoshi myopathy. <span><span class="ref-journal">Neuromuscul Disord. </span>2001;<span class="ref-vol">11</span>:139–45.</span> [<a href="/pubmed/11257469" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11257469</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.vilchez.2005.1256">Vilchez JJ, Gallano P, Gallardo E, Lasa A, Rojas-Garcia R, Freixas A, De Luna N, Calafell F, Sevilla T, Mayordomo F, Baiget M, Illa I. Identification of a novel founder mutation in the DYSF gene causing clinical variability in the Spanish population. <span><span class="ref-journal">Arch Neurol. </span>2005;<span class="ref-vol">62</span>:1256–9.</span> [<a href="/pubmed/16087766" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16087766</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.walter.2013.26">Walter MC, Reilich P, Thiele S, Schessl J, Schreiber H, Reiners K, Kress W, M&#x000fc;ller-Reible C, Vorgerd M, Urban P, Schrank B, Deschauer M, Schlotter-Weigel B, Kohnen R, Lochm&#x000fc;ller H. Treatment of dysferlinpathy with deflazacort: a double-blind, placebo-controlled clinical trial. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2013;<span class="ref-vol">8</span>:26.</span> [<a href="/pmc/articles/PMC3617000/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3617000</span></a>] [<a href="/pubmed/23406536" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23406536</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="miyoshi.REF.weiler.1999.871">Weiler T, Bashir R, Anderson LV, Davison K, Moss JA, Britton S, Nylen E, Keers S, Vafiadaki E, Greenberg CR, Bushby CR, Wrogemann K. Identical mutation in patients with limb girdle muscular dystrophy type 2B or Miyoshi myopathy suggests a role for modifier gene(s). <span><span class="ref-journal">Hum Mol Genet. </span>1999;<span class="ref-vol">8</span>:871–7.</span> [<a href="/pubmed/10196377" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10196377</span></a>]</div></li></ul></div></div><div id="miyoshi.Chapter_Notes"><h2 id="_miyoshi_Chapter_Notes_">Chapter Notes</h2><div id="miyoshi.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>5 March 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>22 April 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 April 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>5 February 2004 (me) Review posted live</div></li><li class="half_rhythm"><div>24 September 2003 (ma) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1303</span><span class="label">PMID: <a href="/pubmed/20301480" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301480</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/duarte-gal/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/dkc/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1303&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1303/?report=reader">PubReader</a></li><li><a href="/books/NBK1303/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1303" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1303" style="display:none" title="Cite this Page"><div class="bk_tt">Aoki M. Dysferlinopathy. 2004 Feb 5 [Updated 2015 Mar 5]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1303/pdf/Bookshelf_NBK1303.pdf">PDF version of this page</a> (195K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#miyoshi.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#miyoshi.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#miyoshi.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#miyoshi.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#miyoshi.Genetically_Related_Allelic_Diso" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#miyoshi.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#miyoshi.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#miyoshi.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#miyoshi.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#miyoshi.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#miyoshi.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#miyoshi.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=8291[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">DYSF</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1462556" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1462556" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1462556" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1462556" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301490" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Calpainopathy</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Calpainopathy<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Angelini C, Fanin M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23193613" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ANO5</i> Muscle Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ANO5</i> Muscle Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Penttilä S, Vihola A, Palmio J, Udd B. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301559" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Caveolinopathies</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Caveolinopathies<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bruno C, Sotgia F, Gazzerro E, Minetti C, Lisanti MP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301676" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Collagen Type VI-Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Collagen Type VI-Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lampe AK, Flanigan KM, Bushby KM, Hicks D. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301468" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Muscular Dystrophy Overview</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Congenital Muscular Dystrophy Overview<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sparks SE, Quijano-Roy S, Harper A, Rutkowski A, Gordon E, Hoffman EP, Pegoraro E. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301480" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301480" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5dfc8f93dde089116931b125">Dysferlinopathy - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Dysferlinopathy - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-20T04:08:35-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE88451CDFC83B210000000005AC028E&amp;ncbi_session=CE88451CDFC8F921_1452SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1303%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1303&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1303/&amp;ncbi_pagename=Dysferlinopathy - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE88451CDFC8F921_1452SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>